Evidence map›Paper›PMID 35751013›Full record

ArticleJournal of neurodevelopmental disorders2022

Calculating genetic risk for dysfunction in pleiotropic biological processes using whole exome sequencing data.

Olivia J Veatch, Diego R Mazzotti, Robert T Schultz, Ted Abel, Jacob J Michaelson, Edward S Brodkin, Birkan Tunc, Susan G Assouline, Thomas Nickl-Jockschat, Beth A Malow and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Olivia J VeatchDepartment of Psychiatry and Behavioral Sciences, Medical Center, University of Kansas, Kansas City, KS, USA. oveatch@kumc.edu.
Diego R MazzottiDivision of Medical Informatics, Department of Internal Medicine, Medical Center, University of Kansas, Kansas City, KS, USA.
Robert T SchultzCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Ted AbelDepartment of Neuroscience and Pharmacology, Iowa Neuroscience Institute, University of Iowa, Iowa City, Iowa, USA.
Jacob J MichaelsonDepartment of Psychiatry, University of Iowa, Iowa City, Iowa, USA.
Edward S BrodkinDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Birkan TuncCenter for Autism Research, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Susan G AssoulineBelin-Blank Center for Gifted Education and Talent Development, University of Iowa, Iowa City, Iowa, USA.
Thomas Nickl-JockschatDepartment of Psychiatry, University of Iowa, Iowa City, Iowa, USA.
Beth A MalowDivision of Sleep Medicine, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
James S SutcliffeDepartment of Molecular Physiology and Biophysics, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, USA.
Allan I PackDivision of Sleep Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
University of Iowa · USUniversity of Kansas Medical Center · USUniversity of Pennsylvania · USCenter for Autism and Related Disorders · USChildren's Hospital of Philadelphia · USVanderbilt University · USVanderbilt University Medical Center · US

Funding

TRAINING PROGRAM/RESPIRATORY NEUROBIOLOGY AND SLEEPT32HL007713 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PACK, ALLAN I · 1992 to 2022
$11.9M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Lea K Davis · 2020 to 2026
$10.3M
University of Iowa Hawkeye Intellectual and Developmental Disabilities Research Center (Hawk-IDDRC)P50HD103556 · NICHD · UNIVERSITY OF IOWA · PI EDWIN TED G. ABEL, Lane Strathearn · 2021 to 2026
$8.5M
Efficient Translation of Genetics Research for Clinical Decision SupportK01LM012870 · NLM · UNIVERSITY OF PENNSYLVANIA · PI VEATCH, OLIVIA J · 2018 to 2020
$537k
NHLBI NIH HHS HL07713NHLBI NIH HHS T32 HL007713NICHD NIH HHS P50 HD103537NICHD NIH HHS P50 HD103556NLM NIH HHS K01 LM012870U.S. National Library of Medicine LM012870
6 · The paper itself

Abstract

backgroundNumerous genes are implicated in autism spectrum disorder (ASD). ASD encompasses a wide-range and severity of symptoms and co-occurring conditions; however, the details of how genetic variation contributes to phenotypic differences are unclear. This creates a challenge for translating genetic evidence into clinically useful knowledge. Sleep disturbances are particularly prevalent co-occurring conditions in ASD, and genetics may inform treatment. Identifying convergent mechanisms with evidence for dysfunction that connect ASD and sleep biology could help identify better treatments for sleep disturbances in these individuals.

methodsTo identify mechanisms that influence risk for ASD and co-occurring sleep disturbances, we analyzed whole exome sequence data from individuals in the Simons Simplex Collection (n = 2380). We predicted protein damaging variants (PDVs) in genes currently implicated in either ASD or sleep duration in typically developing children. We predicted a network of ASD-related proteins with direct evidence for interaction with sleep duration-related proteins encoded by genes with PDVs. Overrepresentation analyses of Gene Ontology-defined biological processes were conducted on the resulting gene set. We calculated the likelihood of dysfunction in the top overrepresented biological process. We then tested if scores reflecting genetic dysfunction in the process were associated with parent-reported sleep duration.

resultsThere were 29 genes with PDVs in the ASD dataset where variation was reported in the literature to be associated with both ASD and sleep duration. A network of 108 proteins encoded by ASD and sleep duration candidate genes with PDVs was identified. The mechanism overrepresented in PDV-containing genes that encode proteins in the interaction network with the most evidence for dysfunction was cerebral cortex development (GO:0,021,987). Scores reflecting dysfunction in this process were associated with sleep durations; the largest effects were observed in adolescents (p = 4.65 × 10

conclusionsOur bioinformatic-driven approach detected a biological process enriched for genes encoding a protein-protein interaction network linking ASD gene products with sleep duration gene products where accumulation of potentially damaging variants in individuals with ASD was associated with sleep duration as reported by the parents. Specifically, genetic dysfunction impacting development of the cerebral cortex may affect sleep by disrupting sleep homeostasis which is evidenced to be regulated by this brain region. Future functional assessments and objective measurements of sleep in adolescents with ASD could provide the basis for more informed treatment of sleep problems in these individuals.

Indexed as

Autism Spectrum DisorderBiological PhenomenaSleep Wake DisordersAdolescentChildExomeExome SequencingHumansAutism spectrum disordersExome sequencingGenetic risk scoresPleiotropySleep durationSystems biology

Identifiers

PMID35751013
PMCPMC9233372
OpenAlexW4283449965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.